0001179110-13-010639.txt : 20130620 0001179110-13-010639.hdr.sgml : 20130620 20130620082826 ACCESSION NUMBER: 0001179110-13-010639 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130619 FILED AS OF DATE: 20130620 DATE AS OF CHANGE: 20130620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 7814330771 MAIL ADDRESS: STREET 1: 119 FOURTH AVE CITY: NEEDHAM STATE: MA ZIP: 02494-2725 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHANNON TIMOTHY M CENTRAL INDEX KEY: 0001207114 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 13923350 MAIL ADDRESS: STREET 1: C/O CURAGEN CORP STREET 2: 555LONG WHARF DR. 11TH FL. CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 edgar.xml FORM 4 - X0306 4 2013-06-19 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001207114 SHANNON TIMOTHY M CO/ CELLDEX THERAPEUTICS, INC. 119 FOURTH AVENUE NEEDHAM MA 02494 1 0 0 0 Common Stock 2013-06-19 4 A 0 2000 A 81212 D Non-Qualified Stock Option (right to buy) 15.20 2013-06-19 4 A 0 2000 0 A 2023-06-19 Common Stock 2000 2000 D On June 19, 2013, the Company awarded 2,000 shares of the Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option and Incentive Plan, subject to time-based forfeiture restrictions. Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Such option vests in four equal quarterly installments beginning September 19, 2013. /s/ Avery W. Catlin, attorney in fact for Timothy M. Shannon 2013-06-20